INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is considered to be one of the most common causes of chronic liver diseases in Western countries. Its prevalence is estimated to be 20-30% in the general population [1] . NAFLD occurs as a histological spectrum of diseases that includes nonalcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Even if NAFLD has always been considered a benign condition, nowadays it is increasingly recognized as a major cause of liver-related morbidity and mortality [2] . In fact, many studies have demonstrated that it may progress to cirrhosis, liver failure, and hepatocellular carcinoma [3] . There is also some evidence regarding the pathophysiological association between NAFLD and insulin resistance and its clinical manifestations, such as obesity, metabolic syndrome and diabetes mellitus [4] . Moreover, given the epidemic spread of such conditions, the epidemiological impact of this pathology could grow [5] . Recently, growing evidence has associated NAFLD with endothelial dysfunction (ED), independently from the presence of insulin-resistance, which is considered a traditional risk factor [6] . Endothelial cells are an important component of the normal vascular wall, which provides an interface between the blood stream and surrounding tissue. Endothelium plays a key role in the physiological maintenance of vascular function J Gastrointestin Liver Dis, September 2017 Vol. 26 No 3: 261-268 by regulating vascular tone, leukocyte adhesion and platelet activation, through the release of vasoactive substances, such as nitric oxide, prostacyclin and endothelin [7] .
The presence of NAFLD in insulin-resistant subjects has been associated with a more severe systemic oxidative stress, independent from metabolic syndrome, adiposity, and adipokines [8] . In fact, patients with NAFLD seem to have more severe oxidative stress than non steatotic insulin resistant subjects, despite similar Insulin Resistance index (HOMA-IR) and adiposity [9] . Even though the mechanisms underlying increased oxidative stress in NAFLD are not yet fully understood, impaired mitochondrial beta-oxidation, dietary saturated fat excess, and reduced antioxidant intake have been proposed as important causative factors [10] . The increase in oxidative stress could induce and worsen necroinflammation and fibrosis in NAFLD: high oxidative stress has been demonstrated to impair very low density lipoprotein secretion, leading to hepatocyte triglyceride accumulation in the hepatocytes [11] , whereas oxidation end products are responsible for the inflammatory cascade triggering an extracellular matrix deposition, influencing the liver fibrosis extent in NAFLD.
As demonstrated in many cardiovascular studies, the first target of an increased pathological oxidative stress is the vascular endothelium, since the consequent ED is considered the pathophysiological basis of cardiovascular diseases [12, 13] . Other studies have recently demonstrated that patients with a histological diagnosis of steatosis, in particular steatohepatitis, show more frequent ED subclinical signs [14] , deranged carotidal intima-media thickness [15, 16] , a higher prevalence of carotidal plaques [17] and initial left ventricular dysfunction, particularly in non diabetic, non obese, non hypertensive young patients [18] . Non-alcoholic fatty liver disease, diagnosed by ultrasound abdominal scan, represents an independent risk factor for the development of coronary artery disease, also after adjusting for its traditional risk factors, such as obesity, insulin resistance, metabolic syndrome and its components [19] [20] [21] ; this observation leads to the consideration that ED may have a primary role not only in cardiovascular diseases but also in NAFLD.
Since ED seems to intervene in the pathogenesis and natural history of NAFLD, it might be useful to identify an ED biomarker in this setting. Recently, a novel serum biomarker called Endocan (ESM-1) has been found to predict the overall survival in patients with liver cirrhosis [22] . ESM-1 is a 50 kDa circulating proteoglycan specifically produced by non sinusoidal endothelial cells. In vitro, this marker is upregulated in the presence of pro-angiogenic molecules, such as the vascular endothelial growth factor (VEGF), or in the presence of pro-inflammatory molecules, such as tumor necrosis factor-alpha (TNF-alpha) or lipopolysaccharides. Moreover, ESM-1 was shown to bind to the intercellular adhesion molecule (I-CAM) and to the lymphocyte functionassociated antigen 1 (LFA-1), and to inhibit transendothelial migration of leukocytes during inflammation, all factors that could demonstrate its active role, even during sepsis [23] .
Data suggests a role of Endocan as a marker of ED. Nault et al. showed an increase of Endocan serum levels in patients with alcoholic cirrhosis, and it seemed to predict a worse outcome and a higher risk of developing hepatocellular carcinoma [24] . Moreover, Sherpereel et al. clearly demonstrated a positive correlation between Endocan serum levels and a poor prognosis in septic patients [23] . Other studies explored the role of ESM-1 in a wide variety of pathological processes, such as cancerogenicity, pre-eclampsia, systemic sclerosis, obstructive sleep apnea, deep vein thrombosis and acute respiratory distress syndrome [24] [25] [26] [27] [28] [29] .
In light of this, the aim of the present study was to investigate Endocan serum levels in patients with NAFLD with or without type 2 diabetes mellitus (T2DM).
METHODS
This observational study is in compliance with the ethical guidelines of the Declaration of Helsinki (1975) and was approved by the Institutional Review Board at our Center (number 0018123/2015).
Consecutive NAFLD patients with or without T2DM were enrolled, according to inclusion/exclusion criteria, after signing an informed consent. The definition of the presence/absence of NAFLD, the etiology and the staging of the disease were diagnosed after exclusion of other causes of liver diseases (hepatitis B virus infection, hepatitis C virus infection, hemocromatosis, Wilson disease, autoimmune hepatitis, alcoholic hepatitis, primary biliary cholangitis, sclerosing cholangitis), by serological tests and clinical data and by performing an abdomen ultrasound and/or a liver biopsy.
Absence or presence of NASH was evaluated according to standard histopathological criteria and the severity of the disease was assessed by using NAS (non-alcoholic fatty liver disease activity score) established by Kleiner et al. [30] , as the sum of scores of steatosis, lobular inflammation and hepatocellular ballooning. At histological analysis a NAS score ≥ 5 was considered diagnostic for NASH. Fibrosis was scored according to Brunt et al. [31] , as stage 0 (none), stage 1 (zone 3 perisinusoidal or portal fibrosis), stage 2 (zone 3 perisinusoidal and periportal fibrosis without bridging), stage 3 (bridging fibrosis).
Diagnostic criteria used for T2DM were: random venous plasma glucose concentration ≥ 200 mg/dl or a fasting plasma glucose concentration ≥ 126 mg/dl measured at two different evaluations or two hours plasma glucose concentration ≥ 200 mg/dl two hours after 75g anhydrous glucose in an oral glucose tolerance test.
Medical history, alcohol consumption, drug intake, current drug treatments, smoking habits, blood pressure, weight and height for the calculation of body mass index (BMI), and waist/ hip ratio (WHR) were investigated. Additional data included routine laboratory tests (blood glucose, total cholesterol, high density lipoprotein, triglycerides, aspartate and alanine aminotransferases, gamma-glutamyltranspeptidase, alkaline phosphatase, blood count), obtained by peripheral venous samples; other blood samples were collected in order to properly evaluate Endocan serum concentration. Inclusion criteria were: presence of NAFL or NASH with or without T2DM and/or metabolic syndrome, capacity to understand and follow study protocol and willingness to participate in the study, expressed by the signing of the informed consent. Exclusion criteria were:
J Gastrointestin Liver Dis, September 2017 Vol. 26 No 3: 261-268 serious complications related to diabetes (i.e. IV stage chronic kidney disease, proliferative diabetic retinopathy, diabetic foot infections etc.), major systemic diseases, unwillingness to participate in the study and to sign the informed consent, drug abuse history or psychological/psychiatric problems that could invalidate the informed consent, and other known active ED causes, such as sepsis, cardiovascular diseases and cancer.
Endocan serum level assessment
We determined Endocan concentration after collecting peripheral blood samples and centrifuging them for serum extraction. Sera were tested by enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's instructions (Human Endocan / ESM-1 DIY ELISA Kit, Endomark H1, Lunginnov sas, Lille, France) [32] .
In brief, standards, positive control and samples were added into microassay wells, already covered with anti-human Endocan monoclonal antibody, which binds to Endocan present in standards, positive controls and samples. After incubation, washing discarded unbound materials. AntiEndocan monoclonal antibody (which binds on capture Endocan during the first step) conjugated to biotin was added into the wells. After incubation and washing, the lectin conjugated to horseradish peroxidase (HRP) was added into all the wells. HRP binds onto the immobilized biotin-conjugate monoclonal antibody. After incubation and washing, the bound Endocan was detected by chromogenic reaction of tetramethylbenzidine substrate solution (TMB) in the presence of HRP. The optical density was determined using a microplate reader set at 450 nm and a wavelength correction set at 630 nm. The colour intensity of the colour is proportional Endocan concentration in diluted samples, standards and positive controls. The results were calculated from the standard curve, drawn using the linear regression method. Each serum sample was assayed for Endocan in triplicate, and the mean value was used as the result.
Sample size calculation
The sample size of the present study was based on recent findings on the usefulness of serum proteoglycans as prognostic markers of disease gravity in alcoholic cirrhosis and hepatocellular carcinoma [24] .
Nevertheless, no certain pathological values of Endocan have already been identified, because they largely depend on the type of patient settings (oncologic, hypertensive, diabetic). According to the cited literature, a 40% difference in Endocan serum levels has to be considered significant. On the basis of this assumption, the required sample size was calculated to be 18 patients for each group using a two-tailed test, with a 0.05 α error and a 90% statistical power ("STATA 10 for MacIntosh", "Two samples comparison of Proportions"). 
Statistical analysis

RESULTS
On the basis of the purposes of this study, 56 patients who showed the inclusion criteria and 25 healthy subjects were enrolled. These patients were divided into 19 patients with ultrasound and/or histological diagnosis of NAFLD without T2DM, and 37 patients with diagnosis of T2DM with or without NAFLD.
Demographical characteristics of our study population are reported in Table I . There were no statistically significant differences in the proportion of race/ethnicity and gender between subgroups. Mean age of NAFLD patients was lower compared to diabetic ones.
Endocan level significantly higher in NAFLD subjects, independently from the presence of T2DM, compared to controls (1.23±1.51 vs 0.68±0.4 ng/mL; p=0.016) (Fig. 1) .
We further examined levels of Endocan by dividing NAFLD patients into two groups on the basis of the presence/absence of necroinflammation and fibrosis: steatosis (NAFL) patients (35) , and steatohepatitis (NASH) patients (16) .
Endocan serum levels were higher in NAFL and NASH patients compared to controls (1.12±1.11, 1.49±2.16 and 0.68±0.4 ng/ml respectively), independently from the presence of diabetes; the increase was more marked in NASH patients compared to the NAFLD ones (p=0.001 and p=0.004 vs controls, respectively), although it was not statistically significant between the two groups (p=0.448) (Fig. 2) . Fig. 2 . Serum levels of Endocan (ng/ml) in controls, non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). The increase was more marked in NASH patients compared to NAFL ones (**p=0.001 and *p=0.004 vs controls, respectively), even if it was not statistically significant between the two groups (p=0.448).
Fig. 3.
Serum levels of Endocan (ng/ml) in non-diabetic non-alcoholic fatty liver disease (NAFLD) and diabetic NAFLD patients. This marker was increased in diabetic patients compared to non diabetic subjects (*p=0.001), independently from liver disease. No statistically significant differences were found between controls and NAFLD without diabetes (p=0.06).
Furthermore, we studied Endocan in non-diabetic NAFLD patients compared to diabetic NAFLD ones, and we found a statistically relevant increase of this marker in diabetic patients compared to non diabetic subjects (1.56±0.81 vs 0.72±0.58 ng/ml; p=0.001), independently from liver disease. No statistical differences were found between controls and NAFLD without diabetes (0.72±0.58 vs 0.68±0.4 ng/ml; p=0.06) (Fig. 3) .
We also evaluated 5 patients with T2DM without steatosis. In these patients Endocan serum levels were similar to those in NAFLD patients with T2DM (1.61±1.54 vs 1.56±0.81 ng/ ml; p=n.s.).
Univariate analysis proved that the male gender (in both NAFLD and diabetes), obesity (in diabetes) and calcium channel blockers (CCBs) assumption (in NAFLD) are factors significantly associated with Endocan serum levels (Table II) .
Calcium channel blockers in NAFLD group and male gender in the diabetic group were independent ED prognostic indicator in a multivariate analysis (Table III) .
DISCUSSION
In this study, we compared Endocan serum levels in patients with histological and/or ultrasound diagnosis of NAFLD, with or without T2DM. Our results have provided three important insights about these potential associations: 1) Endocan levels showed a significant increase in NAFLD patients if compared to controls. Specifically, a more marked increase was found in NASH patients, compared to those with simple steatosis; 2) J Gastrointestin Liver Dis, September 2017 Vol. 26 No 3: 261-268
Endocan levels were significantly increased in diabetic patients compared to non diabetic ones; 3) in agreement with the results obtained by other research groups, Endocan levels were not significantly higher in NAFLD patients without diabetes compared to healthy subjects; the presence of diabetes type II in NAFLD patients was responsible for a statistically relevant increase of Endocan serum levels.
To further confirm this last result, we also studied 5 patients with T2DM without steatosis, who are rarely observed in clinical practice. In these patients Endocan serum levels were similar to those in NAFLD patients with T2DM.
We chose to investigate Endocan serum levels in NAFLD and T2DM patients because both diseases are associated with ED. A great amount of evidence suggested that ED is an important component in NAFLD pathogenesis: it has been demonstrated that both steatosis and steatohepatitis may cause an extensive involvement of vascular system, that could promote the progression to fibrosis and cirrhosis [33] . We found that NAFLD was associated with a statistically significant increase in Endocan serum levels compared to controls, as shown in Fig. 1 . This increase was more marked in steatohepatitis, compared to simple steatosis, independently from the presence of T2DM (Fig. 2) . With respect to this last point, morbidity and mortality correlated to T2DM are usually caused by its vascular complications. In this case, the altered endothelial function is determined by the decrease of HDL-cholesterol, the higher production of reactive oxigen species (ROS), the increase of oxidized low density lipoproteins (LDLs), the increase of circulating free fatty acids and the production of cytokines, such as TNFalpha and adiponectin [34] [35] [36] . Furthermore, according to our data, recent studies have shown higher Endocan levels in T2DM patients [37] . In line with the results of this study, we found a significant increase of this marker in diabetic subjects compared to non diabetic ones. We interpreted this finding as a further step to confirm the reliability and scientific relevance of Endocan as a marker of endothelial damage. On the basis of these preliminary data, depending on the presence of T2DM, we split the NAFLD patients (Fig. 3) . To the best of our knowledge, no other studies have specifically investigated an increase of Endocan levels in diabetic NAFLD patients compared with non diabetic NAFLD ones. Several studies demonstrated that the presence of NAFLD could adversely affect the development of vascular complications and a more severe prognosis in diabetic subjects [39] ; therefore, it appears clear that T2DM, in patients with NAFLD could cause an important ED that could determine an increase of our marker. An interesting element to be discussed is the age of the patients enrolled in this study: the mean age of NAFLD-only patients (without diabetes) was considerably lower than the age of diabetic subjects (Table I ). This could be explained by considering that NAFLD and T2DM share some pathophysiological mechanisms, such as insulin-resistance and endothelial damage, but NAFLD may precede and predict the development of T2DM [39] . Moreover, we found that Endocan serum levels did not differ significantly in NAFLD patients without diabetes compared to healthy subjects (Fig. 3) . This result may appear to be in conflict with previous studies [40] showing an increase of this marker in this liver pathology. However, after a deeper inspection, we noticed that all these studies described an increase of Endocan serum levels in NAFLD patients only if it was associated with other well known causes ED, such as cardiovascular diseases, sepsis, chronic kidney disease or neoplasms. On the basis of our hypothesis, Tok et al. [41] found lower Endocan levels in NAFLD patients with no other important systemic pathologies, compared to controls; however, the present study was limited by both a relatively small sample size and a non-trustful diagnosis of NASH due to the impossibility of performing a liver biopsy in all recruited patients. With respect to these results, univariate and multivariate analysis proved that there are some factors that could increase the risk of Endocan derangements. Univariate analysis showed statistical significance for male gender (both in NAFLD and T2DM), obesity (in diabetes) and CCBs assumption (in NAFLD). However, only male gender in the diabetic group and CCBs assumption in NAFLD group were found by using a multivariate analysis to be independent prognostic indicators. As regards the effect of CCBs, our results seem to disagree with the data in literature, which attest a protective effect of these drugs over the endothelium system [42] . Further studies will be necessary in order to explore the connection between CCBs and endothelium system.
In our opinion, this pilot study could be useful for future studies, in order to evaluate Endocan serum levels in patients with metabolic syndrome. Indeed, all the components of this complex pathology may be individually involved in ED. Various studies demonstrated that hypertension, hyperglycemia, obesity, HLD decrease, hypertriglyceridemia and insulinresistance are all factors that could damage vessels by reducing nitric oxide, by increasing ROS production, and by modifying vasodilators/vasoconstrictors ratio [11, [37] [38] [39] .
CONCLUSION
We demonstrated an increased Endocan serum level in NAFLD patients, higher in those with type 2 diabetes mellitus and/or NASH because of an endothelial dysfunction in these pathologies. To our knowledge, no studies have demonstrated the role of Endocan in the systemic vascular damage caused by this syndrome; therefore, we believe that our findings could lead to a deeper insight into this topic.
